Berberine Attenuates TNBS-induced Colitis in Mice by Improving the Intestinal Microbiota

Overview

Journal Front Microbiol

Specialty Microbiology

Date 2024 Sep 13

PMID 39268532

Authors

Chao Li

Xinxin Yin

Changpeng Xie

Jin Zeng

Chuan Song

Guibin Yang

Jinglei Zhang

Siai Chen

Panjian Wei

Ziyu Wang

Meng Gu

Wei Li

Juan An

Yuanming Pan

Affiliations

Soon will be listed here.

Abstract

Objective: To investigate the effects of berberine (BBR) as a treatment on intestinal microecological alterations and enteritis in mice produced by TNBS.

Methods: There were seven mice per group: seven in the healthy group (Ctrl), seven in the TNBS-induced enteritis group (TNBS), and seven in the berberine treatment group (BBR). The mice were weighed, slaughtered after 7 days, and subjected to high-throughput intestinal microecological analysis by Illumina, as well as haematological detection and imaging evaluation of colon pathology.

Results: The alterations in colon length, immune cell subpopulations, inflammatory factors, and intestinal microecology of mice induced by BBR were refined using a battery of experiments and observations. According to intestinal microecological studies, BBR can increase the number of bacteria, including , , , and .

Conclusion: BBR has a therapeutic effect on TNBS-induced colitis in mice, which is associated with modifications in immune cell subpopulations and intestinal microecology. It also offers a viable approach as a prospective probiotic (like ) to IBD therapy in clinical settings.

References

Li R, Chen Y, Shi M, Xu X, Zhao Y, Wu X . Gegen Qinlian decoction alleviates experimental colitis via suppressing TLR4/NF-κB signaling and enhancing antioxidant effect. Phytomedicine. 2016; 23(10):1012-20. DOI: 10.1016/j.phymed.2016.06.010. View

Chassaing B, Aitken J, Malleshappa M, Vijay-Kumar M . Dextran sulfate sodium (DSS)-induced colitis in mice. Curr Protoc Immunol. 2014; 104:15.25.1-15.25.14. PMC: 3980572. DOI: 10.1002/0471142735.im1525s104. View

Gong J, Hu M, Huang Z, Fang K, Wang D, Chen Q . Berberine Attenuates Intestinal Mucosal Barrier Dysfunction in Type 2 Diabetic Rats. Front Pharmacol. 2017; 8:42. PMC: 5290458. DOI: 10.3389/fphar.2017.00042. View

Zheng T, Hao H, Liu Q, Li J, Yao Y, Liu Y . Effect of Extracelluar Vesicles Derived from on Intestinal Barrier in Colitis Mice. Nutrients. 2023; 15(22). PMC: 10674789. DOI: 10.3390/nu15224722. View

Al Ojaimi Y, Khachab M, Bazzi S, Bahr G, Echtay K . Mitochondrial bioenergetics, uncoupling protein-2 activity, and reactive oxygen species production in the small intestine of a TNBS-induced colitis rat model. Mol Cell Biochem. 2020; 470(1-2):87-98. DOI: 10.1007/s11010-020-03749-z. View

Gong M, Duan H, Wu F, Ren Y, Gong J, Xu L . Berberine Alleviates Insulin Resistance and Inflammation Inhibiting the LTB4-BLT1 Axis. Front Pharmacol. 2021; 12:722360. PMC: 8599302. DOI: 10.3389/fphar.2021.722360. View

Zhang Y, Gu Y, Ren H, Wang S, Zhong H, Zhao X . Gut microbiome-related effects of berberine and probiotics on type 2 diabetes (the PREMOTE study). Nat Commun. 2020; 11(1):5015. PMC: 7538905. DOI: 10.1038/s41467-020-18414-8. View

Shou J, Shaw P . Berberine Reduces Lipid Accumulation in Obesity via Mediating Transcriptional Function of PPARδ. Int J Mol Sci. 2023; 24(14). PMC: 10380538. DOI: 10.3390/ijms241411600. View

Cao F, Xia W, Dai S, Wang C, Shi R, Yang Y . Berberine: An inspiring resource for the treatment of colorectal diseases. Biomed Pharmacother. 2023; 167:115571. DOI: 10.1016/j.biopha.2023.115571. View

10.

Yue S, Liu J, Wang W, Wang A, Yang X, Guan H . Berberine treatment-emergent mild diarrhea associated with gut microbiota dysbiosis. Biomed Pharmacother. 2019; 116:109002. DOI: 10.1016/j.biopha.2019.109002. View

11.

Wang Y, Liu Y, Du X, Ma H, Yao J . The Anti-Cancer Mechanisms of Berberine: A Review. Cancer Manag Res. 2020; 12:695-702. PMC: 6996556. DOI: 10.2147/CMAR.S242329. View

12.

Huang B, Gui M, An H, Shen J, Ye F, Ni Z . Babao Dan alleviates gut immune and microbiota disorders while impacting the TLR4/MyD88/NF-кB pathway to attenuate 5-Fluorouracil-induced intestinal injury. Biomed Pharmacother. 2023; 166:115387. DOI: 10.1016/j.biopha.2023.115387. View

13.

Xu Y, Duan J, Wang D, Liu J, Chen X, Qin X . Alleviates Persistent Inflammation, Immunosuppression, and Catabolism Syndrome in Mice. Metabolites. 2023; 13(2). PMC: 9961567. DOI: 10.3390/metabo13020194. View

14.

Zhang Z, Zhang H, Li B, Meng X, Wang J, Zhang Y . Berberine activates thermogenesis in white and brown adipose tissue. Nat Commun. 2014; 5:5493. DOI: 10.1038/ncomms6493. View

15.

Cai Y, Xin Q, Lu J, Miao Y, Lin Q, Cong W . A New Therapeutic Candidate for Cardiovascular Diseases: Berberine. Front Pharmacol. 2021; 12:631100. PMC: 8010184. DOI: 10.3389/fphar.2021.631100. View

16.

Li L, Chang L, Zhang X, Ning Z, Mayne J, Ye Y . Berberine and its structural analogs have differing effects on functional profiles of individual gut microbiomes. Gut Microbes. 2020; 11(5):1348-1361. PMC: 7524264. DOI: 10.1080/19490976.2020.1755413. View

17.

Luo W, Tian L, Tan B, Shen Z, Xiao M, Wu S . Update: Innate Lymphoid Cells in Inflammatory Bowel Disease. Dig Dis Sci. 2021; 67(1):56-66. DOI: 10.1007/s10620-021-06831-8. View

18.

Yang H, Liu Q, Liu H, Kang X, Tian H, Kang Y . Berberine alleviates concanavalin A-induced autoimmune hepatitis in mice by modulating the gut microbiota. Hepatol Commun. 2024; 8(4). PMC: 10932532. DOI: 10.1097/HC9.0000000000000381. View

19.

Zhang H, Wang Z, Wang G, Song X, Qian Y, Liao Z . Understanding the Connection between Gut Homeostasis and Psychological Stress. J Nutr. 2023; 153(4):924-939. DOI: 10.1016/j.tjnut.2023.01.026. View

20.

Sujitha S, Dinesh P, Rasool M . Berberine modulates ASK1 signaling mediated through TLR4/TRAF2 via upregulation of miR-23a. Toxicol Appl Pharmacol. 2018; 359:34-46. DOI: 10.1016/j.taap.2018.09.017. View